Holen Sie sich die Stockscreener-App
100.50
1.52%
-1.55
Schlusskurs vom Vortag:
$102.05
Offen:
$102.17
24-Stunden-Volumen:
1.71M
Relative Volume:
1.70
Marktkapitalisierung:
$6.20B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
14.15
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
-8.67%
1M Leistung:
-26.57%
6M Leistung:
-7.63%
1J Leistung:
-11.45%
1-Tages-Spanne:
$98.59
$102.25
1-Wochen-Bereich:
$95.49
$111.65
52-Wochen-Spanne:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
100.50 | 6.20B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus
Jazz Pharma stock slips after $145M antitrust deal (JAZZ) - Seeking Alpha
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time To Buy Or Sell? - Barchart.com
Jazz Pharmaceuticals stock hits 52-week low at $99 - Investing.com
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st
Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight - Law360
UBS cuts Jazz Pharmaceuticals stock price target to $166 By Investing.com - Investing.com UK
Potential Tariffs Pose Challenges for Jazz Pharmaceuticals (JAZZ) - GuruFocus
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating - MarketScreener
Post-traumatic Stress Disorder Treatment Market Generated - openPR.com
After a year of 4.3% returns, Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) share price drop last week may have less of an impact on institutional investors - Yahoo Finance
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Jazz Pharma Reveals Growth Strategy: Key Updates Coming at Major Healthcare Conference - Stock Titan
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo
Jazz strikes the chord with $935m Chimerix acquisition - BioXconomy
Based On Its ROE, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A High Quality Stock? - simplywall.st
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride - Yahoo Finance
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewswire Inc.
Akari Therapeutics Appoints Biotechnology Industry Leader, - GlobeNewswire
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance
Interesting JAZZ Put And Call Options For October 17th - Nasdaq
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? - Yahoo Finance
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PR Newswire
Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears - Law360
JAZZ or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition? - Yahoo Finance
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Yahoo Finance
Jazz Pharmaceuticals EVP sells shares worth $332,604 By Investing.com - Investing.com South Africa
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Yahoo Finance
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Bull of the Day: Jazz Pharmaceuticals (JAZZ) - Yahoo Finance
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):